Search Results - "Orazem, J P"

Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer by Francis, P A, Rigas, J R, Kris, M G, Pisters, K M, Orazem, J P, Woolley, K J, Heelan, R T

“…This phase II study was conducted to evaluate the efficacy and toxicity of docetaxel in the treatment of patients with advanced non-small-cell lung cancer…”
Get more information

Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole by Rigas, J R, Francis, P A, Muindi, J R, Kris, M G, Huselton, C, DeGrazia, F, Orazem, J P, Young, C W, Warrell, Jr, R P

“…All-trans-retinoic acid (all-trans RA) induces complete remission in most patients with acute promyelocytic leukemia (APL). However, continuous oral dosing…”
Get more information

Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule by RIGAS, J. R, FRANCIS, P. A, MILLER, V. A, TONG, W. P, ROISTACHER, N, KRIS, M. G, ORAZEM, J. P, YOUNG, C. W, WARRELL, R. P

“…The in vitro human tumor colony-forming assay identified chloroquinoxaline sulfonamide (CQS) as an active agent at human plasma concentrations of > 100…”
Get full text

Phase I clinical and pharmacological study of chloroquinoxaline sulfonamide by RIGAS, J. R, TONG, W. P, KRIS, M. G, ORAZEM, J. P, YOUNG, C. W, WARRELL, R. P

“…Chloroquinoxaline sulfonamide (CQS) is a halogenated heterocyclic sulfanilamide identified by the in vitro human tumor colony-forming assay as an active agent…”
Get full text

Three-dimensional conformal radiation therapy in locally advanced carcinoma of the prostate: preliminary results of a phase I dose-escalation study by Leibel, S A, Heimann, R, Kutcher, G J, Zelefsky, M J, Burman, C M, Melian, E, Orazem, J P, Mohan, R, LoSasso, T J, Lo, Y C

“…The acute morbidity of doses of 64.8-75.6 Gy and preliminary observations of late complications and tumor response using 3-dimensional conformal radiation…”
Get more information

Isoflurane versus fentanyl: hemodynamic effects in cancer patients treated with anthracyclines by Thorne, A C, Orazem, J P, Shah, N K, Matarazzo, D, Dwyer, D, Pierri, M K, Hoskins, W J, Rubin, S C, Bedford, R F

“…Cancer patients treated with anthracycline derivatives are at risk for perioperative cardiovascular decompensation. The authors studied hemodynamic performance…”
Get more information